

FORM PTO-1390  
(REV. 9-2001)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

GJE-81

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

10/030868

INTERNATIONAL APPLICATION NO.  
PCT/GB00/01492INTERNATIONAL FILING DATE  
April 17, 2000PRIORITY DATE CLAIMED  
April 19, 1999 and October 20, 1999

## TITLE OF INVENTION

Optical Microscopy and Its Use in the Study of Cells

## APPLICANT(S) FOR DO/EO/US

Yuri Evgenievich Korchev, David Klenerman, Max Joseph Lab

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
  - b. ☒ has been communicated by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
  - a. ☐ is attached hereto.
  - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ have been communicated by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☐ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)) (unsigned).
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

## Items 11 to 20 below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.
14. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. ☐ Other items or information:

U.S. APPLICATION NO. **10/030868** INTERNATIONAL APPLICATION NO. **PCT/GB00/01492** ATTORNEY'S DOCKET NUMBER **GJE-81**

21. ☒ The following fees are submitted:

**BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):**

Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO. .... **\$1040.00**

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... **\$890.00**

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... **\$740.00**

International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... **\$710.00**

International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) ..... **\$100.00**

**ENTER APPROPRIATE BASIC FEE AMOUNT =**

**CALCULATIONS PTO USE ONLY**

**\$890.00**

Surcharge of **\$130.00** for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492(e)).

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$
Total claims	<u>35</u> - 20 =	<u>15</u>	x <b>\$18.00</b>	<b>\$270.00</b>
Independent claims	<u>2</u> - 3 =	<u>0</u>	x <b>\$84.00</b>	<b>\$0.00</b>
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ <b>\$270.00</b>	<b>\$0.00</b>
<b>TOTAL OF ABOVE CALCULATIONS =</b>				<b>\$1,160.00</b>

☐ Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.

+

**SUBTOTAL = \$1,160.00**

Processing fee of **\$130.00** for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492(f)).

**TOTAL NATIONAL FEE = \$1,160.00**

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). **\$40.00** per property +

**TOTAL FEES ENCLOSED = \$1,160.00**

Amount to be refunded: \$

charged: \$

- a. ☐ A check in the amount of \$ \_\_\_\_\_ to cover the above fees is enclosed.
- b. ☒ Please charge my Deposit Account No. 19-0065 in the amount of \$ 1,160.00 to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0065. A duplicate copy of this sheet is enclosed.
- d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

**NOTE:** Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.

CORRESPONDENCE ADDRESS:

**CUSTOMER NUMBER**  
**23,557**

October 18, 2001

DATE

SIGNATURE

Doran R. Pace

NAME

38,261

REGISTRATION NUMBER

October 18, 2001

PRELIMINARY AMENDMENT  
Patent Application  
Docket No. GJE-81

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Yuri Evgenievich Korchev, David Klenerman, Max Joseph Lab  
Docket No. : GJE-81  
For : Optical Microscopy and Its Use in the Study of Cells

Box PCT  
Assistant Commissioner for Patents  
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

It is respectfully requested that the above-identified patent application be amended as follows:

In the Specification

After page 13: Please insert as new page 14 the attached Abstract of the Disclosure.

In the Claims

Please cancel claims 1-17, without prejudice.

Please add the following new claims 18-52:

18. An apparatus for imaging an object, comprising a probe via which an assay component may be delivered; a sensor to detect ion current; and means for controlling the position of the probe relative to the object in response to the ion current.

19. The apparatus according to claim 18, wherein the probe is a micropipette.

20. The apparatus according to claim 18, wherein the assay component is light.

21. The apparatus according to claim 19, wherein the assay component is light.
22. The apparatus according to claim 20, wherein the probe comprises a fibre optic.
23. The apparatus according to claim 20, which additionally comprises a laser light source.
24. The apparatus according to claim 22, which additionally comprises a laser light source.
25. The apparatus according to claim 20, wherein the probe contains a light-activatable dye at its tip.
26. The apparatus according to claim 20, wherein the outer surface of the probe is coated to prevent leakage of light.
27. The apparatus according to claim 20, wherein the outer surface of the probe is coated with a metal layer to prevent leakage of light.
28. The apparatus according to claim 18, wherein the probe contains, as the assay component, a substance that, at the surface of a live cell, produces a detectable change.
29. The apparatus according to claim 19, wherein the probe contains, as the assay component, a substance that, at the surface of a live cell, produces a detectable change.
30. The apparatus according to claim 28, wherein said substance generates fluorescence, bioluminescence or chemiluminescence.
31. The apparatus according to claim 29, wherein said substance generates fluorescence, bioluminescence or chemiluminescence.

32. The apparatus according to claim 18, wherein the probe contains, as the assay component, a substance that, on delivery to a live cell, produces a detectable change inside the cell.

33. The apparatus according to claim 19, wherein the probe contains, as the assay component, a substance that, on delivery to a live cell, produces a detectable change inside the cell.

34. The apparatus according to claim 18, wherein the controlling means comprises means for vibrating the probe substantially normal to the surface of the object, and means for modulating the ion current.

35. A method for imaging an object in a liquid environment, by scanning ionconductance microscopy, using a probe whose distance from the object is maintained in response to the ion current in the liquid, wherein the probe includes means for delivering an assay component to the object.

36. The method according to claim 35, wherein the probe is a micropipette.

37. The method according to claim 35, wherein the probe comprises a fibre optic.

38. The method according to claim 35, wherein the probe contains a light-activatable dye at its tip.

39. The method according to claim 35, wherein the outer surface of the probe is coated with a metal layer to prevent leakage of light.

40. The method according to claim 35, wherein the probe contains, as the assay component, a substance that, at the surface of a live cell, produces a detectable change.

41. The method according to claim 36, wherein the probe contains, as the assay component, a substance that, at the surface of a live cell, produces a detectable change.

42. The method according to claim 41, wherein said substance generates fluorescence, bioluminescence or chemiluminescence.

43. The method according to claim 35, wherein the probe contains, as the assay component, a substance that, on delivery to a live cell, produces a detectable change inside the cell.

44. The method according to claim 36, wherein the probe contains, as the assay component, a substance that, on delivery to a live cell, produces a detectable change inside the cell.

45. The method according to claim 35, wherein the assay component is light.

46. The method according to claim 45, which additionally comprises a laser light source.

47. The method according to claim 35, wherein the probe contains, as the assay component, a substance that, at the surface of a live cell, produces a detectable change.

48. The method according to claim 47, wherein said substance generates fluorescence, bioluminescence or chemiluminescence.

49. The method according to claim 35, wherein the probe contains, as the assay component, a substance that, on delivery to a live cell, produces a detectable change inside the cell.

50. The method according to claim 35, which comprises generating light and wherein the said distance is less than the wavelength of the light.

51. The method according to claim 35, wherein the probe is vibrated substantially normal to the surface of the object, and the distance is controlled by modulation of the ion current.

52. The method according to claim 35, wherein the object is a live cell.

51. The method according to claim 35, wherein the probe is vibrated substantially normal to the surface of the object, and the distance is controlled by modulation of the ion current.

52. The method according to claim 35, wherein the object is a live cell.

Remarks

The Commissioner is hereby authorized to charge any fees under 37 CFR §§1.16 or 1.17 as required by this paper to Deposit Account No. 19-0065.

Respectfully submitted,



Doran R. Pace  
Patent Attorney  
Registration No. 38,261  
Phone No.: 352-375-8100  
Fax No.: 352-372-5800  
Address: 2421 N.W. 41st Street, Suite A-1  
Gainesville, FL 32606-6669

DRP/sl

Attachment: Abstract of the Disclosure



OPTICAL MICROSCOPY AND ITS USE IN THE STUDY OF CELLSField of the Invention

This invention relates to optical microscopy and its use in the study of cells.

Background of the Invention

5       The cell is the most fundamental unit of living organisms, whether animal or plant. The study of its structure and composition, and how its various constituents function, lends valuable insight into the complex processes that occur in integrated biological systems. This requires techniques that allow investigation of cell samples to be conducted in real-time, non-invasively, and in solutions that mimic physiological  
10       conditions so that cell functionality is retained.

Optical microscopy (using visible light) has been widely applied to study live cells. However, the resolution is limited by diffraction to about 200-250 nm. For more detailed study, one commonly used method is electron microscopy, where it is possible to obtain images with 10 nm resolution, but the sample needs to be fixed prior  
15       to imaging. Hence, it is not possible to use an electron microscope to study living cells.

Another possible high resolution technique is based on the use of scanning probe microscopy (SPM), in which a sharp probe tip is scanned in close proximity to the sample under study. The consequent interactions and thus the chemical/physical  
20       properties of the sample can be plotted as a function of the tip's position with respect to the sample, to generate a profile of this measured interaction. Members of the SPM family that are commonly applied to biological imaging are atomic force microscopy (AFM), scanning ion-conductance microscopy (SICM) and scanning near-field optical microscopy (SNOM).

25       In SNOM, light is normally coupled down a fibre-optic probe with an output aperture of sub-wavelength dimensions, which is scanned above the sample surface. Interaction forces between the tip and sample are used to maintain their separation at less than the sub-wavelength dimensions of the aperture. This arrangement allows simultaneous generation of optical and topographic images whose resolution depends  
30       on the size of the output aperture and the size of the tip respectively. As in far field optical microscopy, all contrast mechanisms are available in SNOM, and in particular chemical imaging is possible by the use of fluorescent labels. However, while it is straightforward to fabricate probes with smaller apertures, achieving smaller tip-sample separations in liquid (<60 nm) is difficult because of the problems in obtaining a

reliable method of controlling the probe-sample distance. This is due to damping of the oscillations of the probe used in the feedback mechanism.

In SICM, an electrolyte-filled, glass micropipette is scanned over the surface of a sample bathed in an electrolytic solution; see Hansma *et al* (1989) Science 243:641-3. The pipette-sample separation is maintained at a constant value by controlling the ion-current that flows via the pipette aperture. The flow is between two electrodes: one inside the pipette and another outside in the electrolyte solution. For an applied bias between the electrodes, the ion-current signal depends on a combination of the micropipette's resistance ( $R_p$ ) and the access resistance ( $R_{AC}$ ) which is the resistance along the convergent paths from the bath to the micropipette opening.  $R_p$  depends on the tip diameter and cone angle of the micropipette, whereas  $R_{AC}$  displays complicated dependence on the sample's electrochemical properties, geometry and separation from the probe. It is  $R_{AC}$  that lends ion-current sensitivity to the pipette-sample separation and allows its exploitation in maintaining the distance such that contact does not occur.

The optimum tip-sample separation that has allowed SICM to be established as a non-contact profiling method for elaborated surfaces, is equal to one-half of the tip diameter; see Korchev *et al* (1997), J. Microsc. 188:17-23, and also Biophys. J. 73:653-8. The tip's output is used to generate topographic features and/or images of the local ion-currents flowing through pores on the sample surface. The spatial resolution achievable using SICM is dependent on the size of the tip aperture, and is typically between 50 nm and 1.5  $\mu\text{m}$ . This produces a corresponding resolution.

#### Summary of the Invention

In order to meet the objective of high resolution microscopic study of cells that are alive, and not fixed, a hybrid scanning ion conductance and scanning near field optical microscope has been developed. Accordingly, in one aspect of this invention, apparatus comprises a probe via which an assay component may be delivered; a sensor to detect ion current; and means for controlling the position of the probe relative to the object in response to the ion current. In another aspect, a method for imaging an object in a liquid environment, by scanning ion-conductance microscopy, uses a probe whose distance from the object is maintained in response to the ion current in the liquid, wherein the probe includes means for delivering an assay component to the object.

The present invention is based in part on a realisation that SICM and SNOM techniques are complementary (SICM as a non-contact profiling method and SNOM as a technique that allows acquisition of optical and chemical information pertaining to a sample) and that they can be used to advantage if they are in one experimental arrangement.

Use of the novel apparatus allows quantitative, high-resolution characterisation of the cell surface and the simultaneous recording of topographic and optical images. A particular feature of the method is a reliable mechanism to control the distance between the probe and the sample in liquid, e.g. physiological buffer.

The new method has been demonstrated by recording near field images of living cells (cardiac myocytes) for the first time. Straightforward modifications to the instrument will enable fluorescence imaging and higher resolution.

The invention allows functional mapping of cells. For example, it allows ion channel mapping.

By means of the invention, it is possible to image the cell surface in a single scan, by using the probe to keep the cell surface in the confocal volume of the microscope. For biological imaging of live cells, the exposure of light can be limited, thereby minimising damage and overcoming the problem of intense near field light sources used in SNOM. Although the cell may alter shape, this is not a problem in this surface confocal mode, since imaging is always at the surface.

A feature of this invention is its simplicity. For example, existing confocal microscopes can readily be retrofitted with a pipette and suitable computer control.

#### Description of the Drawings

A micropipette of the type that may be used in this invention is illustrated in Figure 1 of the accompanying drawings. Figures 2A and 2C illustrate how non-modulated ion current may be used to control probe position over a sample; Figures 2B and 2C illustrate how feedback control may be used, as in a preferred embodiment of this invention. Figure 3 represents another arrangement of components suitable for use in the invention. Figure 4 shows the results of detection of single  $K_{ATP}$  channels in rat cardiomyocyte sarcolemma.

#### Description of the Invention

The term "assay component" is used herein to describe any chemical or physical entity that can be delivered to the locus of observation, and which is either observable *per se* or can generate an observable response. For example, the assay

component may be light; a laser may be provided, so that, for example, coherent light can be directed, *via* the probe, to a cell surface. Alternatively, possibly again in combination with a laser source, the probe may contain at its tip a material, such as a light-activatable dye, that will generate light *in situ*. The outer surface of the probe  
5 may be coated, e.g. with a metal layer, to prevent leakage of light.

A suitable micropipette is shown schematically in Figure 1. It comprises a pipette body 10 having the metal coating 11 at its tip. Laser light from a source (not shown) is launched down a fibre optic 12.

Thus, for example, a micropipette is filled with one or more fluorophors and  
10 excited with a laser. In one case, the laser comes up the microscope objective; this produces a local light source since the laser is focussed at the tip of the pipette. In addition, the dye is concentrated, so that the depth of penetration of the laser light into solution is very small. The dye is under pressure and so slowly leaks out of the pipette, avoiding problems in photobleaching. This can be used to image in the near  
15 field; no metal coating is required.

In another embodiment, the assay component is a chemical reagent, and this reagent may act directly or indirectly. Examples of reagents that have a direct effect include those that generate fluorescence, bioluminescence or chemiluminescence. Thus, for example, a micropipette may be adapted to deliver luciferin that is acted on  
20 by luciferase in the presence of ATP and magnesium ions, to produce light peaking at 568 nm. Magnesium may be provided in the solution and all the other reagents in the pipette, so that light is produced locally by the reaction. No coating is needed to produce the near field light source. Rapid dilution of reagents, once they emerge from the pipette, means that the light is produced at the tip and the resolution is determined  
25 by the aperture of the pipette.

Other suitable reagents include molecules that change fluorescence with variation in a particular property such as pH, in concentration, e.g. of Ca, or potential. Local application of appropriate reagents and excitation of the fluorophor allows local probing of this property, e.g. map channel or proton pumps.

30 Examples of reagents that act indirectly are those that, on delivery to the cell, product a change inside the cell, as a result of transduction. It is that change which is detected. This effect may be naturally amplified by the signal cascade.

More specifically, the pipette may contain a ligand or drug. This acts on or binds a receptor on the cell surface. Inside the cell, as a result of the signal

transduction cascade, there is a change in the level of a secondary messenger, for example in the cell's calcium level. There is amplification of the binding event by the cascade where an enzyme is turned on, producing many product molecules which in turn act on many other enzymes etc., so that one binding event results in a large change. This naturally amplified signal is detected, for instance, using a fluorescence dye, e.g. fluor-3, which binds calcium in the cell, and can be used to measure calcium concentration. A large change in calcium can be seen when the pipette is over the receptor. Since calcium is the most common messenger used by the cell, this is a general method. It does not involve the use of fluorescently-labelled antibodies to detect where a receptor is located. Antibodies, particularly monoclonal, can be hard to produce and can have problems that they are internalised in the cell. Other fluorescence markers can be used for other common messengers in the cell, such as cAMP.

The present invention may be illustrated by modification of an existing SICM system, to allow simultaneous generation of SICM and SNOM images of living cardiac myocyte cells. In order to illustrate the utility of such apparatus, cardiac myocyte cells were chosen, for two main reasons. Firstly, they are composed of light and dark bands of material/striations that occur periodically, every 2.1  $\mu\text{m}$ , which give them a distinct appearance and therefore make them a good model system for study. Secondly, and more importantly, they constitute heart muscle chambers that synchronously contract to produce the crucial pumping activity to circulate blood to the rest of the body. These cells have previously been studied using SICM (Korchev *et al, supra*).

The experiments presented here have provided the first images of live cells taken using scanning near field optical microscopy and show that scanning ion conductance microscopy provides a reliable control mechanism for SNOM imaging of live cells. The images of cardiomyocytes have the widely accepted structure and dimensions: comparable, for example, to those found with electron microscopy. By comparison, an important advantage of this invention is that the cells are unfixed and alive.

Although a simple hybrid SICM-SNOM instrument already has the potential to be a powerful investigative tool, straightforward modifications can be made, to improve its sensitivity and resolution. Firstly, smaller coated pipettes may improve both the SICM and SNOM resolution and increase the size of the optical signals, by holding the

near field probe closer to the sample. For example, high resolution SNOM probes may be made by tapering and coating a micropipette for imaging in air using force control (Harootunian *et al*, 1986). An optical resolution less than 100 nm was obtained. This indicates that fabrication of higher resolution near field probes for SICM-SNOM is feasible. Using a higher numerical aperture objective for collection of the light can further increase the optical signal. These improvements will enable fluorescence imaging and also minimise problems in photobleaching and photodamage by working at minimum laser intensity. It is easier to photodamage living cells than fixed cells, so reducing the required laser power is important in order to be able to take multiple scans over time. These improvements in combination should enable the obtaining of simultaneous SICM and SNOM images with a resolution better than 100 nm on live cells.

In particular, by using the ion current to control the distance between a coated micropipette and the sample, it is possible to obtain simultaneous optical and SICM images. The optical images are obtained in the near field and hence this appears to be a reliable way to perform SNOM imaging of live cells. This is the first time that has been achieved. Straightforward improvements to the instrument should enable fluorescence imaging and higher resolution to be obtained. Combination with fluorescence imaging may allow one to image receptors and channels on the surface of live cells and to follow changes in the response to specific stimuli. The new method of SICM-SNOM imaging of live cells has a wide range of possible applications in biological science.

In a preferred embodiment of the invention, a frequency-modulated scanning protocol for a scanning ion conductance microscope (SICM) is used. This may comprise means to vibrate a SICM probe in a vertical direction (Z) and to use this modulation for feedback control of the microscope.

Figs. 2A and 2B show schematically a micropipette 20 (also in dotted outline in Fig. 2B) in an electrolyte 21 within a vessel 22 having a sample 23 at its base. Electrodes 24 and 25 are connected via a circuit including a meter 26 providing feedback control (represented by the arrow). Fig. 2C shows tip current as a function of the sample-tip separation.

In conventional SICM microscopes, non-modulated ( $I_{DC}$ ) ion current (Figs. 2A and 2C) is used to control the probe position over the sample. In that case, any changes in ion current flowing through the micropipette tip which are not caused by

the probe/sample interaction (changes in ion concentration, interaction of the micropipette tip with contaminating particles in aqueous solutions, drift of electrode potential, etc) produce artefacts or crash the sample and the micropipette. In the frequency-modulated mode of SICM operation, the movement of the microscope tip ( $\Delta Z$ ) generates modulated current ( $I_{MOD}$ ). This  $I_{MOD}$  is only generated when the probe senses the sample and is used for feedback control of the microscope; see Figs. 2B and 2C (insert). The feedback control mainly uses, for example, the frequency-modulated scanning protocol, as it has a number of additional advantages over a non-modulated mode: greater signal/noise ratio; high stability (ability to operate in a large gradient of electrolyte and with high  $I_{DC}$  drift); higher scan speed; increase in lateral sensitivity.

A typical SICM system comprises components that feature in all SPMs, namely, scanning probe, piezo-actuator scanning elements, control electronics and a computer. These components may be built in and around an inverted microscope, e.g. Diaphot 200 (Nikon Corporation, Tokyo, Japan).

The following Examples illustrate the invention. Further evidence of the utility of this invention is provided, indirectly, by Lewis *et al* (1999), Applied Physics Letters 75(17):2689-91. This utilises AFM, for control of chrome etching.

#### Example 1

SICM probes are fabricated by pulling borosilicate glass microcapillaries with outer and inner diameters of 1.00 mm and 0.58 mm respectively, using a laser-based micropipette puller (Model P-2000, Sutter Instrument Co., San Rafael, CA, USA). This reproducibly and easily produces probes with conical taper lengths and apex diameters of 200 nm, 400 nm and 1.0  $\mu$ m, respectively.

Three-dimensional and high precision movement of the probe relative to the sample is achieved using a piezo-translation stage (Tritor 100, Piezosystem Jena, Germany) on which the SICM probe is mounted. The stage has a range of 100  $\mu$ m in the x, y and z directions, so that scanning over biological samples, with features that scale up to 30-50  $\mu$ m, is made possible. The high voltage required for deformation of the piezo-ceramic material that facilitates the stage's movement is provided by high voltage amplifiers (Piezosystem Jena, Germany). These amplifiers respond to appropriate signals generated by the control electronics, to drive the piezo-translation stage and achieve movement of the tip relative to the sample. In addition to being connected with the hardware aspect of the microscope, the control electronics

interface with a computer that allows data acquisition and image analysis. The control/data acquisition hardware and software are produced by East Coast Scientific (Cambridge, UK).

5 The pipette-sample separation is maintained at a constant value by monitoring the ion-current that flows between Ag/AgCl electrodes in the micropipette and electrolyte solution in which the sample is immersed. Phosphate-buffered saline (PBS) solution is used for both filling the micropipette and the electrophysiological medium of the cardiac myocytes, so that concentration cell potentials and liquid junction potentials are not established. The ion-current is measured for DC voltages  
10 of 50 mV applied to the electrodes. It is amplified by means of a high-impedance operational amplifier (OPA129, Bull Brown International, USA) and converted to a voltage signal over a resistance of  $10^8 \Omega$ . This signal is then inputted into the control electronics where it is used for feedback control and data acquisition.

The micropipette is housed in a special, custom-made holder which is  
15 assembled together with the current amplifier and piezo-translation stage to comprise the SICM head. The SICM head is mounted onto the arm of the inverted microscope's z-translator that facilitates coarse vertical positioning of the micropipette relative to the sample positioned immediately below it. The sample is contained in a petri dish which is placed on the microscope's stage. Movement of the sample relative to the  
20 micropipette is achieved by the x,y translation controls of the stage. The processes of monitoring the vertical position of the micropipette relative to the sample and selection of an area of interest on the sample can be viewed on a TV screen via a video camera (JVC TK-1280E, Victor Company, Japan).

Modifications were made, in order to permit simultaneous SICM and SNOM  
25 imaging. Laser light (Laser 2000 Ltd., UK) of wavelength 532 nm, was coupled via a multi-mode fibre (FG-200-UCR; 3M Specialty Optical Fibers, West Haven, USA) into the micropipette. In order to confine light of the aperture, 100-150 nm of aluminium was evaporated onto the walls of the pipette. The scattered laser light was collected by a x60 long working distance objective and relayed by transfer optics onto a PMT  
30 (D-104-814, Photon Technology International, Surbiton, England) to record the optical signal. During raster scan, this signal was recorded on the data acquisition computer, via an ADC, which also recorded the z position of the sample, to obtain simultaneous optical and topographic images of the sample using the control/data acquisition hardware and software.



Adult rabbit myocytes were isolated using a low calcium solution (NaCl 120, KCl 5.4, MgSO<sub>4</sub> 5, pyruvate 5, glucose 20, taurine 20, HEPES 10 and nitrotriactic acid 5 (mmol/L), preoxygenated with 100% O<sub>2</sub>) and collagenase and protease enzymes, as described by Jones *et al* (1990) Cardiovasc. Res. 24:834-842. Cells were imaged on a glass coverslip in a low calcium medium at room temperature.

Optical and SICM images were recorded simultaneously. It took about 20 minutes to record one set of images. The micropipette was estimated, by the measured ion current, to have an internal diameter of about 500 nm and was held about 250 nm over the surface during imaging. The estimated external diameter was 1000 nm, and comprises the glass and metal coating. This means that these images were recorded in the near field, less than the wavelength of light from the sample, with an aperture having a diameter comparable to the wavelength of light.

A 20 x 20 µm scan of the surface of a living rabbit cardiac myocyte showed that the sarcomeric structure was clearly visible in both the SICM and SNOM images. The optical image appeared to be generated only at the surface of the cell as expected using a scanning probe technique. In a larger scan range, there was excellent correspondence between the optical and SICM images. The estimated resolution was about 500 nm.

### Example 2

This Example again illustrates the focal, highly localized application of ions, agonists, or other agents to a membrane during a scan via the microscope micropipette. Monitoring the electrical response of the cell is conducted with a patch-clamp micropipette. This arrangement is illustrated schematically in Fig. 3.

More particularly, Fig. 3 shows schematically a scanning micropipette whose tip is adjacent to an ion channel in a cell. A patch clamp micropipette provides ion channel current recording.

This Example investigates the distribution of ATP-regulated K<sup>+</sup> channels (K<sub>ATP</sub> channels) in rat cardiomyocyte sarcolemma. K<sub>ATP</sub> channels play important roles in the relaxation and preservation of cardiomyocytes during metabolic stress such as hypoxia or ischemia. Very little is known about their localization in the cell membrane. Experimental conditions were chosen so that intra- and extracellular solutions contain no K<sup>+</sup> ions, and the intracellular ATP concentration was reduced to provide maximum activation of K<sub>ATP</sub> channels.

Before measurements, the cell was perfused, and intracellular and extracellular  $K^+$  was substituted by  $Cs^+$  and  $Na^+$  respectively. The intracellular solution contained no ATP. The cell was clamped at 0 mV. Prior to channel mapping, extracellular  $Na^+$  was replaced for a short time by  $K^+$  to ensure that the intracellular ATP level is sufficiently low to observe strong ATP-regulated  $K^+$  current. Under these conditions, but in the presence of ATP, this current is not observed. The microscope micropipette probe contains permeable ions -  $K^+$  (1M), and as it scans the cell surface, it supplies  $K^+$  ions to a highly localized area under the micropipette tip. When  $K^+$  concentration increases near the active ion channel, the patch-clamp micropipette records increased  $K^+$  current (Fig. 4A). The dotted line represents zero current.

The observed ion current profile is bell-shaped, which is as expected from the distribution of  $K^+$  ions around the micropipette tip. The maximum value of negative current corresponds to the position of the scanning micropipette tip when it is exactly above the ion channel, and is proportional to the  $K^+$  concentration in the micropipette. This current value closely matches the amplitude of single  $K_{ATP}$  channel current observed in outside-out patches studied under similar ionic conditions (Fig. 4B), where the bath  $K^+$  concentration is equal to that supplied by the scanning micropipette.

These procedures allow two images (shown as the single profiles across a cardiac myocyte surface, Figs. 4C & 4D) to be obtained simultaneously. One is the topographical image of the cell surface (Fig. 4C). The other is an 'ion current' image (Fig. 4D), where each point corresponds to the value of ion current measured by the patch clamp pipette. This is plotted using the co-ordinates of the microscope micropipette tip on the cell surface at the time of measurement. Two current peaks directed downwardly, that correspond to the positions of individual ion channels, are clearly visible in Fig. 4D, and vertical arrows indicate their positions on the cardiac myocyte surface (Fig. 4C).

Active ion channels spend part of their time in the closed state and can easily remain undetected during a short period of measurement. In order to increase the probability of single channel detection, the current was acquired through the same single channel during several profile records of the scan.

Analysis of a large number of current images revealed that  $K_{ATP}$  channels are non-uniformly distributed, being concentrated in the localized regions of the cardiac myocyte sarcolemma. Each of these regions or "clusters" is separated by 2-6  $\mu m$  from the others and contains up to 10 active ion channels. The ion channels within the

"cluster" are 0.2-1  $\mu\text{m}$  apart. The  $K_{\text{ATP}}$  channels could be recorded at the same locations in the sarcolemma during relatively long periods of observation (more than 40 min). Furthermore, the active  $K_{\text{ATP}}$  channels were observed only in "scallop"-like regions of sarcolemma, and not in other parts of the plasma membrane (e.g. the regions of cellular contacts). This suggests that the  $K_{\text{ATP}}$  channels are anchored, probably by the cytoskeleton, in specific regions of the sarcolemma and have very low lateral mobility. This direct observation is in good accord with published results, that indicate that there is some link between the F-actin cytoskeleton and the  $K_{\text{ATP}}$  channels; see Yokoshiki *et al*, Pflugers Arch. 434-203 (1997).

This technique can be used to study the distribution of other types of ion channels in cardiomyocytes. Also, the approach will have general application in the investigation of the ion channel functional localization in intact cell membranes of different cell types.

CLAIMS

1. Apparatus for imaging an object, comprising a probe via which an assay component may be delivered; a sensor to detect ion current; and means for controlling the position of the probe relative to the object in response to the ion current.
- 5 2. Apparatus according to claim 1, wherein the probe is a micropipette.
3. Apparatus according to claim 1 or claim 2, wherein the assay component is light.
4. Apparatus according to claim 3, wherein the probe comprises a fibre optic.
5. Apparatus according to claim 3 or claim 4, which additionally comprises a laser
- 10 light source.
6. Apparatus according to any of claims 3 to 5, wherein the probe contains a light-activatable dye at its tip.
7. Apparatus according to any of claims 3 to 6, wherein the outer surface of the probe is coated, e.g. with a metal layer, to prevent leakage of light.
- 15 8. Apparatus according to claim 1 or claim 2, wherein the probe contains, as the assay component, a substance that, at the surface of a live cell, produces a detectable change.
9. Apparatus according to claim 8, wherein said substance generates fluorescence, bioluminescence or chemiluminescence.
- 20 10. Apparatus according to claim 1 or claim 2, wherein the probe contains, as the assay component, a substance that, on delivery to a live cell, produces a detectable change inside the cell.
11. Apparatus according to any preceding claim, wherein the controlling means comprises means for vibrating the probe substantially normal to the surface of the
- 25 object, and means for modulating the ion current.
12. A method for imaging an object in a liquid environment, by scanning ion-conductance microscopy, using a probe whose distance from the object is maintained in response to the ion current in the liquid, wherein the probe includes means for delivering an assay component to the object.
- 30 13. A method according to claim 12, wherein the probe is as defined in any of claims 2, 4 and 6 to 10.
14. A method according to claim 12 or claim 13, wherein the assay component is as defined in any of claims 3, 5, 8, 9 and 10.

15. A method according to any of claims 12 to 14, which comprises generating light and wherein the said distance is less than the wavelength of the light.
16. A method according to any of claims 12 to 15, wherein the probe is vibrated substantially normal to the surface of the object, and the said distance is controlled by modulation of the ion current.
- 5 17. A method according to any of claims 12 to 16, wherein the object is a live cell.

Abstract of the Disclosure

The present invention pertains to an apparatus for imaging an object, comprising a probe via which an assay component may be delivered; a sensor to detect ion current; and means for controlling the position of the probe relative to the object in response to the ion current. Such apparatus can be used to image live cells, without affecting them, in solution, *e.g.*, using light, wherein the distance between probe and cell is less than the wavelength of light.

Fig.1.





Fig.3.



2/4







Fig.2C.




Fig.4A.




Fig.4B.



Fig.4C.





Fig.4D.



## DECLARATION AND POWER OF ATTORNEY

USA  
GJE-81

As a below-named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name; I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of subject matter which is claimed and for which a patent is sought on an invention entitled  
**OPTICAL MICROSCOPY AND ITS USE IN THE STUDY OF CELLS**

the specification of which ☐ is attached hereto or

☒ was filed on 17 APR 2000 as United States Application Number or PCT International Application Number PCT/GB00/01492 and was amended on (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56. I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for a patent or inventor's certificate, or PCT international application having a filing date before that of the application on which priority is claimed:

Prior Foreign Application Number(s)	Country	Foreign Filing Date	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
9908932.8	GB	19 APR 1999	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
9924880.9	GB	20 OCT 1999	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: David R. Saliwanchik, Reg. 31,794; Jeff Lloyd, Reg. 35,589; Doran R. Pace, Reg. 38,261; Christine Q. McLeod, Reg. 36,213; Jay M. Sanders, Reg. 39,355; James S. Parker, Reg. 40,119 and Jean E. Kyle, Reg. 36,987; Frank C. Eisenschenk, Reg. 45,332; Seth M. Blum. Reg. 45,489

Customer No. 23552

Direct all correspondence to:  
Saliwanchik, Lloyd & Saliwanchik  
2421 N.W. 41st Street, Suite A-1  
Gainesville, FL 32606-6669  
USA

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C 1001 and that such willful false statements may jeopardise the validity of the application or any patent issued thereon.

1 - 00 Full name of sole or First Inventor Yuri Evgenievich KORCHEV

Inventor's signature



Residence address London, United Kingdom GBX

Post Office address


Dept. of Medicine, Imperial College School of Medicine at the Hammersmith Campus, Du Cane Road, London W12 0NN, United Kingdom

Country of Citizenship United Kingdom

Date of signature 18/10/2001

2 - 00 Full name of Second Inventor David KLENERMAN

Inventor's signature



Residence address Cambridge, United Kingdom GBX

Post Office address

University of Cambridge, Dept. of Chemistry, Lensfield Road, Cambridge CB2 1EW, United Kingdom

Country of Citizenship United Kingdom

Date of signature 18/10/2001

3 - 00 Full name of Third Inventor Max Joseph LAB

Inventor's signature



Residence address London, United Kingdom GBX

Post Office address

Dept. of Medicine, Imperial College School of Medicine at the Hammersmith Campus, Du Cane Road, London W12 0NN, United Kingdom

Country of Citizenship United Kingdom

Date of signature 18.10.2001